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Sammanf In conjunction with rehydration. the bisphosphonates are the treatment of choice for hypercal-
caemia of malignancy. Single infusions of either pamidronate or clodronate are usuallY effective, but a direct
comparison of the two agents given at the highest doses commonly used has not been performed. Forty-one
patients (15 breast. 12 squamous carcinomas. four lymphomas. four bladder, two prostate and four others)
vVith hypercalcaemia of malignancy (corrected serum calcium >2.7 mmol 1-') persisting after 48 h of saline
rehydration were randomly allocated to receive a 4 h intravenous (i.s.) infusion of either pamidronate 90 mg
or clodronate 1500 mg. No other systemic anti-cancer treatment was prescribed. There were no significant
differences in the post-hydration serum calcium values (mean 3.17 mmol 1` for pamidronate and
3.06 mmol 1- for clodronate). tumour type or frequency of bone metastases between the two treatments. One
patient on each treatment died within 2 days and was not assessable for response. A total of 19 19 (100%)
patients achieved normocalcaemia following pamidronate and 16 20 (800 o) with clodronate. The median time
to achieve normocalcaemia was 4 days (range 2-14) for pamidronate and 3 days (range 2-6) with clodronate.
The median duration of normnocalcaemia was 28 days (range 10-28 + days) after pamidronate and 14 days
after clodronate (range 7-21 days) (P<0.01). Two patients who failed to respond to clodronate were
successfully treated with pamidronate and achieved normocalcaemia for 14 and >28 days respectively. Two
patients experienced fever after pamidronate but no significant toxicity was observed with either treatment. We
conclude that both agents are effective in the management of hypercalcaemia of malignancy. At the doses
studied. the effects of pamidronate are more complete and longer lasting than those of clodronate.
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Hypercalcaemia is a common metabolic complication of
malignancy and complicates the clinical course of 5-10% of
patients with advanced cancers (Fisken et al., 1980). Intra-
venous volume expansion to correct dehydration (Hosking et
al., 1982), coupled with bisphosphonate therapy to inhibit
bone resorption has for some years been the treatment of
choice (Ralston et al., 1985; Witte et al., 1987; Singer, 1990).
Despite the efficacy of treatment, recurrence of hypercal-
caemia occurs unless effective treatment for the underlying
cancer is possible. In many situations this cannot be achieved
and the median survival for patients with hypercalcaemia of
malignancy is less than 3 months (Ralston et al., 1985; Witte
et al., 1987; Singer, 1990; O'Rourke et al., 1994).
Three bisphosphonates are currently licensed for the treat-
ment of hypercalcaemia of malignancy in the UK. They are
etidronate (Didronel), clodronate (Bonefos, Loron) and
pamidronate (Aredia). Both pamidronate and clodronate
have been shown to be superior to treatment with etidronate
which is the weakest inhibitor of bone resorption (Kanis et
al., 1987; Ralston et al., 1989; Gucalp et al., 1992). There has
been only one previous randomised comparison of clodro-
nate and pamidronate which showed a more complete and
durable control of hypercalcaemia with pamidronate (Ral-
ston et al., 1985). However, the doses of both clodronate and
pamidronate were lower than currently recommended. In this
study we have performed a randomised comparison of the
two agents at the maximum currently recommended dosages
(Thiebaud et al., 1988; Nussbaum et al., 1993; O'Rourke et
al., 1993). The aim was to identify any difference in duration
of normocalcaemia following treatment with clodronate or
pamidronate.
Patients and methods
We studied 41 patients with hypercalcaemia of malignancy
associated with various tumour types (Table I). Patients were
eligible for treatment when adjusted serum calcium was
>2.7mmoll-1, and if they remained hypercalcaemic after
48 h of rehydration with 31 of normal saline per day.
Patients were randomly allocated to receive either pami-
dronate 90 mg or clodronate 1500 mg. both administered in
500ml of normal saline over 4h. All treatments were
administered on an inpatient basis and intravenous hydration
was continued at 2-31-'day-' until normocalcaemia was
achieved. No other systemic anti-cancer treatment or drugs
known to influence bone metabolism were administered dur-
ing the period of hypercalcaemia and when possible for a
total of 28 days after bisphosphonate administration to
enable the duration of normocalcaemia to be assessed.
Two days before treatment with the bisphosphonate and
on the morning of bisphosphonate treatment and on days 2,
4, 7, 10, 14, 21 and 28 thereafter, blood and urine were
collected for analyses. These included measurement in the
blood of haemoglobin, platelets and white cells including a
differential white cell count. Serum calcium. albumin, phos-
phate, urea. creatinine. and alkaline phosphatase were
measured by Technicon SMAC. Serum calcium was adjusted
for fluctuations in albumin concentrations. Measurements of
calcium, creatiine and hydroxyproline in urine were per-
formed on the second voided, early morning sample of urine
collected over a 2 h period after an overnight fast and
acidified before storage at -20'C. Calcium and hydroxy-
proline concentrations were expressed as a ratio of creatinine
concentration. Routine observations including temperature
were recorded at least twice daily.
The protocol defined retreatment of hypercalcaemia as
follows. Those failing to respond to the first bisphosphonate.
or developing recurrence of hypercalcaemia within 7 days
were to be retreated with the alternative agent, whereas those
developing recurrent hypercalcaemia more than 7 days after
initial treatment were to be retreated with the same bisphos-
phonate. Any patient experiencing a third episode of hyper-
calcaemia was to receive the alternative bisphosphonate. The
blind remained unbroken to study investigators and
patients
It was not anticipated that a clinically important difference
in the frequency of achieving normocalcaemia (adjusted
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Table I Details of tumour type, treatment and mean post-hydration urinary and
cakim serm
Pamidonate (n =20) Clokdonate (n = 21)
Bow metastases Bone mctatas
Tunour type positie negative positive negative
Breast 5 - 10 -
Squamous 3 4 - 4
Lymphoma I I 1 2
Bladder 2 1 1 -
Prostate - - 2
Others 2 1 1 -
Mean post-hydration 3.17 3.06
serum calcum (mmol 1')
Mean post-hydration 1.92 1.77
urmnary calcium
(mmol mmol-' creatinme)
One patent died In each arm within 2 days of randomisation.
serum calcium <2.65 mmolI 1) could be detected and the
study size was desgned to identify an anticipated doubling of
the duration of normocakcemia from 10 days for clodronate
to 20 days for pamidronate. The duration of normocacaemia
was defined as the time from bisphosphonate treatment to
recurrence of hypercalcemia (adjusted serum calcium
>2.60mmoll'). Patients who failed to achieve normocal-
caemia were excluded from the duration of normocakcemia
analysis. It was planed to recruit 60 patients to the study to
give a 90% chance of detecting this difference but with a
planed interim analysis after recruitment of 40 patients. On
the basis of the interim analysis showing a difference between
treatments which was significant at the P = 0.01 level, the
study was discontinued and the results are reported here.
Symptomatic response was assessed using two question-
naires. The first recorded the intensity of pain, analgesic
consumption and mobility according to the ECOG perfor-
mance status (WHO, 1979) and the second quality of life
(QOL) using the Rotterdam Symptom Checklist (RSCL); (De
Haes et al., 1990). This well-validated instument for measur-
ing QOL in cancer patierts comprises physical functional
and psychological components which when combined give a
global score of QOL. Both of these questionnaires were
completed by the patients before treatment and after 7 and
14 days.
Standard parametric and non-parametric statistical
methods were used for analysis of results. These included
ANOVA, the Mann-Whitney U-test, and paired t-test for
changes during treatment (Mathews et al., 1990). For the
comparison of duration of nornmcalcaemia a
Mann-Whitney life-table analysis was performed. The dura-
tion of normocalcemia was censored if additional anti-
3.75 -
3.5-
cancer treatment was prescribed before the study end at 28
days.
Rests
Of the 41 patients, 20 were allocated to treatment with
pamidronate and 21 to clodronate. The two groups were well
balanced in terms of post-hydration prebisphosphonate treat-
ment serum calcium, urinary calcium excretion and frequency
of bone metastases (Table I).
Two patients died within the first 48 h (one in each treat-
ment group) owing to progressive malignancy and could not
be included in the efficacy analysis. Of the 39 evaluable
patients, all 19 treated with pamidronate became normocal-
caemic compared with 16/20 (80%) patients given clodronate
(P= >0.1). The median time to normoacaemia was 3 days
for clodronate and 4 days with pamidronate. Figure 1 shows
the adjusted serum calcium for the two groups and Figure 2
the actuarial analysis for the duration of normocacaemia
(n = 19 for pamidronate and n = 16 for clodronate). The
number of patients observed at each time point is shown in
Figure 2. For clodronate, patients did not reach day 28
because of death due to disease (five patients), too ill to
attend (two patients), required systemic treatment (three
patients) or had recurrence of hypercakaemia. For pamid-
ronate the censored patents were death due to diseas (five
patients), too ill to attend (three patients) or required
systemic treatment (four patients). The median duration of
nor was 14 days (range 7-21 days) following
clodronate treatment and 28 days (range 10->28 days) for
pamidronate (P = 0.01).
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Figures 3a and b show the serial changes in the fasting
urinary excretion of calcium and hydroxyproin respectively.
Urinary calcium decreased following treatment with both
agents but rose again more rapidly following clodronate,
with significant differences (P = <0.01) appearing between
the two groups from 10 days. Changes in hydroxyproline
were less marked but similar to the responses in urine cal-
cium in that there was a significnt decrease in urinary
hydroxyproline in both groups followed by an earler
rebound in the clodronate-treated group.
Figure 4 shows the serial changes in lymphocyte count.
Consistent with advanced malignancy many patients had
suppressd lymphocyte counts before treatment. There was a
small but significnt dcrease (P = <0.05) in lymphocyte
count during the first 7 days in the patients given pami-
dronate, but this was of no clinical signifi. There was no
signifint change in haemoglobin, neutrophils or platelets.
The only toxicity observed was fever during the first 24-48 h
in three patients after administration of pamidronate, requir-
ing treatment with paracetamol. Patients did not report any
other side-effects of treatment. Serum creatinine rose in five
patients treated with clodronate. Figure 5 shows the serial
change in serum creatinine. A steady rise was seen (median
166, range 79-581 Famol 1-') in five patients in the clodronate
treated group between days 2 and 7. No cause could be
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F4_e 2 Actuarial plot to show the duration of normocacaemia
following sucmssful treatmnt of hype acmia in patients given
pamidronate (X= 19, -O-) or codronate (X= 16, ---).
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found for these changes and they occurred before any recur-
rence of hypercalaemia.
The control of hypercacaemia was associated with an
improvement in the pain score in both the treatment groups
after 7 days (Figure 6a). This improvement was more marked
and statistically significant (P = <0.05) in the pamidronate
treated group. Because some of the patients studied were
confused and drowsy, completion of the QOL questionnaires
was incomplete (n = 14 for pamidronate and n = 16 for clod-
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Fgre 5 Serum creatinine following treatment (mean ± s.e.m.).
line).
Pamidronate (n = 20. solid line) and clodronate (n = 21, dotted
ronate). Nevertheless. the limited data collected showed a
significant improvement in QOL following treatment of the
hypercalcaemia. However this was not maintained in the
clodronate group principally owing to recurrence of hypercal-
caemia (Figure 6b).
None of the patients in the pamidronate group showed
primary resistance to treatment. Two patients were success-
fully retreated with pamidronate after recurrence of hypercal-
caemia and one failed to respond to retreatment with either
pamidronate or clodronate. All the other pamidronate
treated patients (n = 16) went onto specific anti-cancer treat-
ment and therefore were not assessable for response to
retreatment. In the clodronate group, two of the four
patients who failed to respond to clodronate were success-
fully treated with pamidronate with a duration of normocal-
caemia of 14 and >28 days. The other two patients were
considered too unwell to justify further intervention and died
with their hypercalcaemia uncontrolled. Four patients were
successfully retreated with clodronate after recurrence of
hypercalcaemia and four failed to respond to retreatment.
Again, all the other clodronate treated patients (n = 12) were
given specific anti-cancer treatment and were not assessable
for response to retreatment.
Both pamidronate and clodronate were effective in treating
hypercalcaemia in this group of patients with advanced
malignancy. The small difference in the response rate was not
significant although it is of interest that two of three patients
with hypercalcaemia resistant to clodronate did respond
satisfactorily to pamidronate. Our study confirms the
hypothesis that the duration of action of pamidronate is
significantly longer than clodronate even when the latter is
given at the maximum recommended dose (O'Rourke et al.,
1993). These results are consistent with those reported by
Ralston et al. (1989). In their study, the proportion of
patients achieving normocalcaemia on day 6 was 14/16
(87.5%) with pamidronate and 6 16 (37.5%) with clodronate
and the duration of normocalcaemia was median 29 (range
18-90) days (n = 6) for pamidronate and 12 (range 9-45)
days (n = 7) for clodronate. The higher response rate in our
study is attnrbutable to the higher doses used (Thiebaud et
al., 1988; Body et al., 1987; Nussbaum et al., 1993). The
observed difference between the two bisphosphonates is due
to the potency and different mechanism of action. Clodro-
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Fge 6 (a) Change in the pain score following treatment
(mean ± s.e.m. expressed as a percentage of the baseline score).
Pamidronate (n = 17. solid line) and clodronate (n = 18 dotted
line). (b) Quality of life as determined by the RSCL
(mean ± s.e.m. expressed as a percentage of the baseline score).
Pamidronate (n = 14. solid line) and clodronate (n = 16, dotted
line).
nate is less potent than pamidronate and acts as a direct
poison to osteoclasts compared wi4l pamidronate which is
not only more potent than clodronite but also inhibits the
osteoclastic activity, and in addition has been shown to
inhibit the precursor cells to become mature osteoclasts
(Fleisch, 1983).
Urinary calcium was suppressed following inhibition of
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bone resorption to a similar extent with both agents but rose
again more rapidly following clodronate. Changes in
hydroxyproline were less marked probably owing to the con-
tribution from non-osseous sources of collagen. e.g. break-
down of soft tissue metastases.
Both treatments were well tolerated apart from fever in
three patients with pamidronate and an increase in serum
creatimne following clodronate in five patients. Fever and
lymphopenia are well-recognised side-effects of pamidronate
and attributed to cytokine release. The fever is generally mild
and transient. It can be treated with paracetamol and
becomes less marked if retreatment is required. Lymphopenia
is generally transient but in our patients appeared to persist
for the duration of observation. The sole unwanted effect of
clodronate was the rise in serum creatinine in five patients
raising the possibility of treatment-related toxicity, this was
unexpected but in none was this attributable to a rise in
serum calcium. Renal toxicity has been reported previously
with both etidronate and clodronate (Bounameaux et al.,
1983) after bolus infusions. However, renal function in
patients with osteoporosis and Paget's disease has been
unaffected by clodronate, while in hypercalcaemia of malig-
nancy an improvement in renal function has generally been
seen. Pamidronate does not appear to have any toxic effects
on the kidney at least up to and including the dose we used.
A small study of pamidronate given at a dose of 90 mg over
1 h showed no effect on either chromium-labelled EDTA
measurement of renal clearance or urinary excretion of N-
acetylglucosamine (NAG) protein and A-microglobulin
(Tyrell et al., 1994). Further studies on the effect of clodro-
nate on renal functions are under evaluation.
In the context of palliation of advanced malignancy. effects
on symptoms and quality of life are of paramount impor-
tance. The bisphosphonates are known to be useful agents
for the treatment of metastatic bone pain (Ernst et al., 1992;
Purohit et al.. 1994; Tyrrell. 1994). In this study pain im-
proved with both pamidronate and clodronate. although only
in the pamidronate-treated group did this reach statistical
significance. In this study we attempted to measure quality of
life using the Rotterdam Symptom Checklist (RSCL) (De
Haes et al.. 1990). Because of the poor medical state of many
of these patients. data could only be collected on a propor-
tion of the patients studied. However it was clear that control
of hypercalcaemia resulted in a reduction in the RSCL score
(improvement in quality of life). After 7 days the RSCL
scores diverged as patients in the clodronate group began to
experience recurrence of hypercalcaemia. These data support.
in a more formal way. previous studies indicating that treat-
ment of normocalcaemia is a useful palliative manoeuvre
which improves quality of life in terminal cancer patients
(Ralston et al.. 1990; Ernst et al.. 1992; Purohit et al.. 1994:
Tyrrell. 1994).
We conclude that both bisphosphonates are effective in the
management of hypercalcaemia of malignancy. At the doses
studied, the effects of pamidronate are more complete and
longer lasting than those of clodronate.
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